7661-25-8

Basic information

• Product Name: 2-Azetidinone, 1-(4-bromophenyl)-
• CAS NO: 7661-25-8
• Molecular Formula: C9H8BrNO
• Molecular Weight: 226.073
• Mol File: 7661-25-8.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2-Azetidinone, 1-(4-bromophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Azetidinone, 1-(4-bromophenyl)-(7661-25-8)
• EPA Substance Registry System: 2-Azetidinone, 1-(4-bromophenyl)-(7661-25-8)

Safety Data

• Hazardous Substances Data: 7661-25-8(Hazardous Substances Data)

Usage

Chemical compound

2-Azetidinone, 1-(4-bromophenyl)-

Also known as

4-bromophenyl-2-azetidinone

Structure

Heterocyclic compound with a five-membered ring structure containing an azetidinone moiety

Uses

Commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals

Biological activities

Studied for its antimicrobial, antiviral, and antitumor properties

Additional applications

Investigated as a ligand in coordination chemistry and as a chiral auxiliary in asymmetric synthesis

Versatility

Exhibits versatile applications in medicinal and agricultural chemistry

Upstream product

• 930-21-2 2-azetidinone 
• 106-37-6 1.4-dibromobenzene 
• 106-40-1 4-bromo-aniline 
• 19205-70-0 3-chloro-N-(4-bromophenyl)propanamide 
• 7661-10-1 3-bromo-N-(4-bromophenyl)propanamide 
• 76227-94-6 ethyl 3-(4-bromophenylamino)propanoate 
• 186581-53-3 diazomethane 
• 2493-02-9 4-bromophenyl isocyanate 

Downstream Products

• 76228-06-3 6-bromo-2,3-dihydro-4(1H)-quinolinone 

Relevant articles and documents

Enantioselective Synthesis of Cyclopropanone Equivalents and Application to the Formation of Chiral β-Lactams

Cyclopropanone derivatives have long been considered unsustainable synthetic intermediates because of their extreme strain and kinetic instability. Reported here is the enantioselective synthesis of 1-sulfonylcyclopropanols, as stable yet powerful equivalents of the corresponding cyclopropanone derivatives, by α-hydroxylation of sulfonylcyclopropanes using a bis(silyl) peroxide as the electrophilic oxygen source. This work constitutes the first general approach to enantioenriched cyclopropanone derivatives. Both the electronic and steric nature of the sulfonyl moiety, which serves as a base-labile protecting group and confers crystallinity to these cyclopropanone precursors, were found to have a crucial impact on the rate of equilibration to the corresponding cyclopropanone. The utility of these cyclopropanone surrogates is demonstrated in a mild and stereospecific formal [3+1] cycloaddition with simple hydroxylamines, leading to the efficient formation of chiral β-lactam derivatives.

Cathepsin K inhibitor and application thereof

The invention relates to a cathepsin K inhibitor and an application thereof, and specifically, relates to a compound and a drug composition thereof used for treating or preventing cathepsin dependence diseases, and the compound and the composition containing the compound can be used as a bone resorption inhibitor to treat relevant diseases. The cathepsin includes but is not limited to cathepsin K.

Synthesis of 2,3-dihydro-4(1H)-quinolones and the corresponding 4(1H)-quinolones via low-temperature fries rearrangement of N-arylazetidin-2- ones

N-Arylazetidin-2-ones of the general form 1, which are readily prepared by GoldbergBuchwald-type copper-catalyzed coupling of N-unsubstituted azetidin-2-ones with the relevant aryl halide or using Mitsunobu cyclization processes, undergo smooth Fries-rearrangement in triflic acid at 018°C to give the isomeric 2,3-dihydro-4(1H)-quinolones (2). Dehydrogenation of the latter compounds using 10% Pd on C in 1.0M aqueous sodium hydroxide/propan-2-ol mixtures at ca. 82°C provides the corresponding 4(1H)-quinolones (3).